Format

Send to

Choose Destination
PLoS One. 2015 Mar 20;10(3):e0121776. doi: 10.1371/journal.pone.0121776. eCollection 2015.

Humoral immunity links Candida albicans infection and celiac disease.

Author information

1
Université Lille Nord de France, Lille, France; UDSL, Lille, France; Service des Maladies de l'Appareil Digestif et de la Nutrition, Lille, France.
2
CHRU, Lille, France.
3
Université Lille Nord de France, Lille, France; UDSL, Lille, France; INSERM U995, Lille, France.
4
Université Lille Nord de France, Lille, France; UDSL, Lille, France; EA2694, Lille, France; Pôle de Santé Publique Registre INSERM/InVS EPIMAD, Lille, France.
5
INSERM U995, Lille, France.
6
Departamento de Enfermeria 1, Escuela Universitaria de Enfermeria, Universidad del Pais Vasco, 48940 Leioa, Spain.
7
Innobiochips, 1 rue du Professeur Calmette, 59000 Lille, France.
8
Université Lille Nord de France, Lille, France; UDSL, Lille, France; INSERM U995, Lille, France; CHRU, Lille, France.
9
Groupe d'Etude des Interactions Hôte-Pathogène, UPRES-EA 3142, Université d'Angers, Angers, France.
10
CHRU, Lille, France; Institut d'Immunologie, Pôle de Biologie, Lille, France.
11
Université Lille Nord de France, Lille, France; UDSL, Lille, France; INSERM U995, Lille, France; Service de Parasitologie Mycologie, Institut de Microbiologie, Lille, France; CHRU, Lille, France.
12
Service des Maladies de l'Appareil Digestif et de la Nutrition, Lille, France; Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.

Abstract

OBJECTIVE:

The protein Hwp1, expressed on the pathogenic phase of Candida albicans, presents sequence analogy with the gluten protein gliadin and is also a substrate for transglutaminase. This had led to the suggestion that C. albicans infection (CI) may be a triggering factor for Celiac disease (CeD) onset. We investigated cross-immune reactivity between CeD and CI.

METHODS:

Serum IgG levels against recombinant Hwp1 and serological markers of CeD were measured in 87 CeD patients, 41 CI patients, and 98 healthy controls (HC). IgA and IgG were also measured in 20 individuals from each of these groups using microchips sensitized with 38 peptides designed from the N-terminal of Hwp1.

RESULTS:

CI and CeD patients had higher levels of anti-Hwp1 (p=0.0005 and p=0.004) and anti-gliadin (p=0.002 and p=0.0009) antibodies than HC but there was no significant difference between CeD and CI patients. CeD and CI patients had higher levels of anti-transglutaminase IgA than HC (p=0.0001 and p=0.0039). During CI, the increase in anti-Hwp1 paralleled the increase in anti-gliadin antibodies. Microchip analysis showed that CeD patients were more reactive against some Hwp1 peptides than CI patients, and that some deamidated peptides were more reactive than their native analogs. Binding of IgG from CeD patients to Hwp1 peptides was inhibited by γIII gliadin peptides.

CONCLUSIONS:

Humoral cross-reactivity between Hwp1 and gliadin was observed during CeD and CI. Increased reactivity to Hwp1 deamidated peptide suggests that transglutaminase is involved in this interplay. These results support the hypothesis that CI may trigger CeD onset in genetically-susceptible individuals.

PMID:
25793717
PMCID:
PMC4368562
DOI:
10.1371/journal.pone.0121776
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center